Pretreatment Systemic Immune-Inflammation Index Can Predict Response to Neoadjuvant Chemotherapy in Cervical Cancer at Stages IB2-IIB.
Pretreatment Systemic Immune-Inflammation Index Can Predict Response to Neoadjuvant Chemotherapy in Cervical Cancer at Stages IB2-IIB.
复制标题
治疗前全身免疫炎症指数可以预测 IB2-IIB 期宫颈癌新辅助化疗的反应
DOI：
10.3389/pore.2022.1610294
复制
发表时间：
2022
影响因子：
2.8
通讯作者：
Zheng, Min
中科院分区：
文献类型：
--
作者：
Liu, Pingping;Jiang, Yinan;Zheng, Xiaojing;Pan, Baoyue;Xiang, Huiling;Zheng, Min
关键词：
背景资料：全身免疫炎症指数（SII）已被确定为各种癌症化疗疗效的预测因子，我们的目的是确定其预测化疗反应的能力和接受铂类新辅助化疗（NACT）的宫颈鳞状细胞癌（CSCC）患者的长期预后。 研究方法：回顾性分析了210例接受NACT的CSCC患者（培训队列中133例，验证队列中77例）的数据。采用Pearson卡方检验、受试者工作特征（ROC）曲线和Logistic回归分析确定SII与病理完全缓解（pCR）之间的相关性。采用Kaplan-Meier法和考克斯比例回归模型分析SII与无进展生存期（PFS）和总生存期（OS）的关系。 结果如下：计算的pCR和生存期的最佳SII截止值分别为568.7051和600.5683，患者分为两组：低SII组（≤568.7051或≤600.5683）和高SII组（>568.7051或>600.5683）。高SII与较低的pCR显著相关。进一步的分析表明，SII是一个更有效的预测pCR比预后营养指数，血小板与淋巴细胞的比例，淋巴细胞与单核细胞的比例。经多因素Logistic回归分析，SII是预测CSCC患者pCR的独立危险因素。Kaplan-Meier分析表明，低SII组的PFS和OS率显著高于高SII组。其他多变量分析表明，SII是接受NACT治疗的CSCC患者的独立预后因素。 结论：结果证实，治疗前SII不仅是pCR的独立预测因子，也是接受含铂NACT治疗的CSCC患者的独立预后因素。
Background: The systemic immune-inflammation index (SII) has been identified as a predictor of chemotherapy efficacy for a variety of cancers, and we aimed to determine its ability to predict the response to chemotherapy and its long-term prognosis for patients with cervical squamous cell carcinoma (CSCC) who have underwent platinum-based neoadjuvant chemotherapy (NACT). Methods: The date from 210 patients (133 in the training cohort and 77 in the validation cohort) with CSCC who received NACT were analyzed retrospectively. The association between SII and the pathological complete response (pCR) was determined using Pearson’s chi-square test, receiver operating characteristic (ROC) curve, and Logistic regression analysis. The Kaplan-Meier method and Cox proportional regression model were used to assess the relationship between SII and progression-free survival (PFS) or overall survival (OS). Results: The calculated optimal SII cutoff values for pCR and survival were 568.7051 and 600.5683, respectively, and patients were divided into two groups: a low SII group (≤568.7051 or ≤600.5683) and a high SII group (>568.7051 or >600.5683). A high SII was associated significantly with a lower pCR. Further analysis determined that SII was a more efficient predictor of pCR than the prognostic nutritional index, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio. Upon multivariate logistic analysis, SII proved to be an independent risk factor to predict the pCR of patients with CSCC. Kaplan-Meier analysis demonstrated that PFS and OS rates were significantly higher in the low-SII group compared with those in the high-SII group. Additional multivariate analysis indicated that the SII is an independent prognostic factor for patients with CSCC treated with NACT. Conclusion: The results confirmed that the pre-treatment SII is not only an independent predictor of pCR but also an independent prognostic factor of CSCC patients treated with platinum based NACT.
登录
查看更多内容
中性粒细胞与淋巴细胞比率和单核细胞与淋巴细胞比率升高以及血小板与淋巴细胞比率降低与多发性骨髓瘤的不良预后相关。
影响因子：
--
作者：
Shi L;Qin X;Wang H;Xia Y;Li Y;Chen X;Shang L;Tai YT;Feng X;Acharya P;Acharya C;Xu Y;Deng S;Hao M;Zou D;Zhao Y;Ru K;Qiu L;An G
通讯作者：
An G
影响因子：
4.9
作者：
Dong, Meilian;Shi, Yonggang;Fan, Ruitai
通讯作者：
Fan, Ruitai
影响因子：
2
作者：
Murakami, Yuki;Saito, Hiroaki;Fujiwara, Yoshiyuki
通讯作者：
Fujiwara, Yoshiyuki
影响因子：
4.7
作者：
Matsumoto, Yuri;Mabuchi, Seiji;Kimura, Tadashi
通讯作者：
Kimura, Tadashi
影响因子：
64.8
作者：
Mellman, Ira;Coukos, George;Dranoff, Glenn
通讯作者：
Dranoff, Glenn